Brokerages Set Qiagen (NYSE:QGEN) PT at $51.15

Shares of Qiagen (NYSE:QGEN) have been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $51.15.

A number of equities research analysts have issued reports on the company. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Thursday, October 17th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $54.00 price objective (up previously from $42.00) on shares of Qiagen in a report on Tuesday, December 10th.

Institutional Trading of Qiagen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tidal Investments LLC acquired a new position in shares of Qiagen in the 3rd quarter valued at about $490,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Qiagen in the third quarter worth $53,000. Sanctuary Advisors LLC lifted its position in Qiagen by 24.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock worth $834,000 after acquiring an additional 3,878 shares during the last quarter. M&T Bank Corp boosted its stake in Qiagen by 1.1% during the 3rd quarter. M&T Bank Corp now owns 85,649 shares of the company’s stock valued at $3,876,000 after purchasing an additional 931 shares during the period. Finally, Barclays PLC grew its stake in shares of Qiagen by 170.6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after acquiring an additional 1,165,594 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Stock Performance

NYSE QGEN opened at $45.34 on Friday. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The stock has a market cap of $10.35 billion, a PE ratio of 116.26, a P/E/G ratio of 3.52 and a beta of 0.35. The stock has a fifty day simple moving average of $43.25 and a 200-day simple moving average of $43.74. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.